Monoclonal gammopathy of undetermined significance doesn't require treatment, but your doctor is likely to recommend periodic checkups to monitor your health.
A checkup six months after diagnosis may be appropriate for most people. If you have a high risk of developing a more serious condition, your doctor may recommend more frequent checkups so that if a disease such as multiple myeloma develops, it can be treated as early as possible. Ask your doctor how often you need to be seen.
A risk-assessment model can predict the risk of progression to multiple myeloma. This model uses the size and type of the abnormal protein and a special blood test called the serum free light chain assay.
If you have monoclonal gammopathy of undetermined significance and bone loss, your doctor may recommend treatment with medications called bisphosphonates that help increase your bone density. Examples of bisphosphonates include alendronate (Binosto, Fosamax), risedronate (Actonel, Atelvia), ibandronate (Boniva) and zoledronic acid (Reclast, Zometa).
May. 17, 2013
- Rajkumar SV. Diagnosis of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed April 3, 2013.
- Rajkumar SV. Clinical course and management of monoclonal gammopathy of undetermined significance. http://www.uptodate.com/home. Accessed April 3, 2013.
- Blade J. Monoclonal gammopathies of undetermined significance. New England Journal of Medicine. 2006;355:2765.
- Rajkumar SV, et al. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: Implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clinic Proceedings. 2010;85:945.
- Therneau TM. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clinic Proceedings. 2012;87:1071.